Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 12, 2021 at 09:41 pm
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was TWD 254.912 million compared to TWD 236.735 million a year ago. Operating income was TWD 19.531 million compared to TWD 17.883 million a year ago. Net income was TWD 11.784 million compared to TWD 16.248 million a year ago. Basic earnings per share was TWD 0.21 compared to TWD 0.29 a year ago. Diluted earnings per share was TWD 0.21 compared to TWD 0.28 a year ago. For the half year, total revenue was TWD 494.391 million compared to TWD 502.419 million a year ago. Operating income was TWD 30.545 million compared to TWD 48.815 million a year ago. Net income was TWD 24.506 million compared to TWD 42.197 million a year ago. Basic earnings per share was TWD 0.43 compared to TWD 0.74 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
